Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688688 · ClinicalTrials.gov registry record · Phase 3
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,792
- Enrollment target
NCT00688688: Completed Phase 3 study, sponsored by Astellas Pharma.
NCT00688688 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 2,792 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (262% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00688688, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,792 participants
- Enrollment target
Study Summary
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
Primary Outcome
An adverse event (AE) was defined as any untoward medical occurrence in a patient administered a study drug and which did not necessarily have a causal relationship with the treatment. The investigator assessed the severity of each AE, including abnormal laboratory values, as follows: Mild: No disruption of normal daily activities; Moderate: Affected normal daily activities; Severe: Inability to perform daily activities.
Interventions
- DRUG Mirabegron
- DRUG Tolterodine
- DRUG Placebo to Mirabegron
- DRUG Placebo to Tolterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,792 participants |
| Start Date | 2008-04-25 |
| Est. Completion | 2010-05-06 |
| Phase | Phase 3 |
What the finished NCT00688688 record still lists
NCT00688688 is an interventional study that assigns participants to a tested intervention. Its 2,792 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (262% higher).
The record links to 0 conditions, and to 4 interventions - of which Mirabegron is the first listed.
NCT00688688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00688688 about?
NCT00688688 is a clinical study titled "Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder". The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
What is the current status of trial NCT00688688?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,792 participants. The study started on 2008-04-25. Estimated completion is 2010-05-06.
What interventions are being tested in trial NCT00688688?
The interventions under investigation include: Mirabegron (DRUG), Tolterodine (DRUG), Placebo to Mirabegron (DRUG), Placebo to Tolterodine (DRUG).
Who is sponsoring clinical trial NCT00688688?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00688688's enrollment target sits among peer trials
2,792 82nd of 2000 higher than 1,919 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI